Pediatric Cancer Biomarkers Market Size, Share & Trends Analysis Report By Indication (Lymphoma, Neuroblastoma, Leukemia, CNS Tumors, Others), By Biomarker (Neuron-Specific enolase (NSE), Alpha-Fetoprotien (AFP), ALK (Anaplastic lymphoma receptor tyrosine kinase gene), CD19, CD20, CD22, Others), By End-User (Hospitals, Oncology Centers, Research Institutions, Diagnostic Laboratories) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2025-2033

Pediatric Cancer Biomarkers Market Size

The global pediatric cancer biomarkers market size was valued at USD 905.79 million in 2024 and is projected to grow from USD 995.76 million in 2025 to reach USD 1,737.24 million by 2033, exhibiting a CAGR of 7.20% during the forecast period (2025-2033).

A biomarker is a biological molecule found in blood, tissues, and other bodily fluids that serves as an indicator of a disease or condition. With the rising prevalence of pediatric carcinos globally, there has been a notable increase in demand for the development of pediatric cancer biomarkers.

Moreover, ongoing innovations in molecular research aimed at the early detection of carcinos in children are significantly driving the market growth. For example, in March 2024, scientists at the University of California, San Francisco, discovered a universal and critical biomarker for neuroblastoma, which could also become a promising target for new treatments.

Pediatric Cancer Biomarkers Market Trends

Using AI for diagnosis of pediatric cancer

Artificial intelligence (AI) is transforming pediatric cancer research by analyzing complex clinical trial data and predicting outcomes. AI's ability to manage large datasets enhances clinical management and diagnosis, aiding in identifying genetic mutations in tumors.

• For example, in April 2023, the National Cancer Institute and Frederick National Laboratory for Cancer Research reported that an AI model effectively predicted pediatric carcinos progression and helped identify genetic mutations in tumors.

Growing focus on early screening and diagnosis

Early screening and diagnosis of pediatric cancer significantly improve survival rates and quality of life. Biomarkers play a pivotal role in enabling early detection, allowing healthcare professionals to choose optimal treatments during the initial stages.

For instance, in January 2024, Cure reported that biomarkers could predict heart problems in childhood cancer survivors, showcasing their potential in improving early diagnosis and post-treatment care.

Thus, early identification not only enhances treatment outcomes but also reduces the overall cost and financial burden associated with carcinos care.

Pediatric Cancer Biomarkers Market Growth Factors

Increasing practice of liquid biopsy

The rising demand for non-invasive diagnostic techniques significantly drives the adoption of liquid biopsies in the global pediatric cancer biomarkers industry. Unlike traditional tissue biopsies, liquid biopsies rely on analyzing genetic biomarkers in body fluids, eliminating the need for invasive procedures. This innovation not only enhances patient comfort but also reduces overall medical costs compared to conventional biopsy methods.

Furthermore, liquid biopsies enable efficient early carcinos detection, real-time monitoring of therapeutic efficacy, and identification of therapeutic targets, making them invaluable for personalized treatment and diagnosis planning.

• For example, in January 2024, News Medical Life Sciences published an article highlighting European researchers utilizing liquid biopsy techniques to target high-risk pediatric cancers, underlining the growing clinical interest in this approach.

Growing prevalence of pediatric cancer globally

The increasing global burden of pediatric cancer is another key driver of market growth. The demand for accurate diagnosis and timely screening has surged as awareness about pediatric carcinos rises. While high-income countries benefit from advanced treatments and higher survival rates, low- and middle-income nations often face challenges such as limited access to diagnostic tools and care facilities.

Environmental factors, genetic predispositions, and lifestyle changes are contributing to a growing incidence of pediatric cancers, including brain cancers, leukemia, lymphomas, and solid tumors.

• For instance, in December 2021, the World Health Organization (WHO) reported that approximately 400,000 children and adolescents aged 0-19 years are diagnosed with cancer annually, highlighting the critical need for effective diagnostic tools like biomarkers to improve outcomes.

Market Restraining Factors

High cost of pediatric cancer biomarkers

The high cost associated with pediatric cancer biomarkers is a significant market restraint. This is primarily due to the extensive clinical research required for their development, validation, and adherence to stringent regulatory standards. Moreover, advanced technologies, such as precision medicine tailored to the genetic profiles of individual patients, further escalate the cost of biomarkers. This limits their commercialization to patients who can afford such specialized diagnostics, creating a barrier to widespread adoption.

• For instance, in July 2022, a scientific paper published in ISPOR Value in Health revealed that the average cost per patient for comprehensive metastatic carcinos biomarker testing is approximately USD 1,669.

Pediatric Cancer Biomarkers Market Opportunities

Integration of pediatric treatment with precision medicine

The integration of precision medicine into pediatric cancer treatment presents a significant opportunity for market growth. Precision medicine enhances therapeutic efficacy by targeting specific biomarkers or genetic profiles, offering tailored solutions for individual patients.

As research continues to advance, combining pediatric treatment protocols with precision medicine has shown promising results in improving survival rates and clinical responses. This creates immense potential for the expansion of pediatric cancer biomarkers in global healthcare.

• For example, in June 2024, researchers and clinicians in Australia demonstrated that precision medicine significantly outperformed conventional therapies, improving survival and clinical outcomes for pediatric cancer patients at high risk.

Regional Insights

North America: Dominant region with 43.8% market share

North America leads the global market, driven by significant investments in childhood cancer initiatives. Organizations like the American Cancer Society Cancer Action Network (ACS CAN) are advocating for substantial funding to improve outcomes for children with carcinos.

• In January 2024, ACS CAN urged Congress to allocate $30 million for the STAR Act, supporting survivorship, treatment access, and research; $50 million for the Childhood Cancer Data Initiative (CCDI); and $51 billion for the NIH, including $10 billion for cancer research at the National Cancer Institute (NCI).

These investments aim to enhance research, improve treatment options, and support childhood cancer survivors, strengthening North America’s market dominance.

Asia-Pacific: Fastest growing region with highest market CAGR

The Asia-Pacific region is the fastest-growing market, fueled by the rising incidence of pediatric cancer in countries like India and China. Improved healthcare infrastructure and supportive government initiatives are driving this growth. In India, public-private partnerships under the National Health Mission have significantly strengthened healthcare policies, expanding access to diagnostics and treatment.

Moreover, increased awareness and investments in healthcare technologies are further boosting the adoption of cancer biomarkers in this region. This rapid growth positions Asia-Pacific as a critical player in the global market.

Country Insights

The pediatric cancer biomarkers industry is experiencing dynamic growth and diversification across the globe, with each country contributing uniquely to the advancement of this transformative field. Below are a few countries that illustrate the diverse contributions and advancements in the global market.

• US.-The U.S. dominates the regional market, driven by a focus on rare cancer research and the rising prevalence of pediatric cancer. According to Congressionally Directed Medical Research, cancer is the leading cause of death in children, with over 1,600 deaths annually, emphasizing the need for innovative biomarkers to improve early detection and treatment outcomes.
• UK–The UK market is expanding due to the increasing prevalence of pediatric cancer. According to the Children’s Cancer and Leukemia Group, approximately 1,635 children are diagnosed with carcinos each year. This growing incidence is driving demand for advanced cancer biomarkers, aiding in early diagnosis and personalized treatments to improve survival rates.
• Canada-Canada’s market is fueled by government investments in pediatric cancer research and rising cases. Data from the Government of Canada reveals nearly 10,000 children live with carcinos, with 1,500 new cases diagnosed annually. This highlights the urgent need for biomarkers to enhance early detection and effective treatment strategies.
• Germany –Germany’s market growth is driven by the rising incidence of pediatric cancer. The Journal of Health Monitoring reports 2,250 new cases annually among children under 18, with leukemia and lymphoma accounting for 50%. These figures underscore the importance of biomarkers for accurate diagnosis and improved outcomes.
• India -India is witnessing rapid growth in the market, with nearly 50,000 children diagnosed annually, according to the Indian Cancer Society. The increasing number of cases emphasizes the demand for innovative biomarkers to enable early detection and improve treatment effectiveness in the country.
• China-China’s market is expanding rapidly due to a rising incidence of childhood cancer. With 22,000 new cases annually and a 2.5% annual increase in malignant tumors among children under 14, the demand for pediatric cancer biomarkers is growing despite limited treatment options for solid tumors.
• Japan-Japan’s market is driven by the increasing prevalence of pediatric cancer. According to the Japan Children’s Cancer Group, 2,500 children are diagnosed annually, with cancer being a significant cause of mortality. This highlights the need for advanced biomarkers to improve treatment outcomes and survival rates.
• Australia –Australia’s market is growing due to rising childhood cancer cases. The HUDSON Institute of Medical Research reports 1,000 new diagnoses annually, with 5,600 children undergoing treatment. This demand for effective biomarkers underscores their critical role in advancing early diagnosis and therapeutic strategies.

Segmentation Analysis

The global pediatric cancer biomarkers market is segmented into indication, biomarker, and end-user

By Indication

Leukemia segment dominates the market with the highest market revenue

The leukemia segment leads the global market due to its high prevalence among children. According to the Children's Hospital of Philadelphia, approximately 4,000 children are diagnosed with cancer annually in the U.S., with one-third of these cases being leukemia. This growing incidence drives the demand for biomarkers to enable early detection and monitor carcinos progression effectively, aiding in timely treatment and diagnosis.

• For example, in November 2024, research by 17 global partner institutions and Professor Terry Dwyer identified molecular markers in blood linked to the progression of acute lymphoblastic leukemia (ALL), enhancing early diagnostic capabilities.

By Biomarker

CD19, CD20, CD22 segment dominates the market with the highest market revenue

The CD19, CD20, and CD22 biomarker segment dominates the market due to their critical role in advanced carcinos therapies. CD19, in particular, is a pivotal target for CAR-T cell therapies, such as axicabtagene ciloleucel, used in treating refractory or relapsed B-cell lymphoma and leukemia. These biomarkers enable precise, targeted treatments that improve outcomes for pediatric patients.

• For instance, therapies targeting CD19 have shown significant success in treating aggressive cancers, making this segment a key contributor to the pediatric carcinos biomarkers market.

By End-User

Hospital segment dominates the market with the highest market revenue

Hospitals dominate the global market as they are the primary centers for cancer diagnosis and treatment. With specialized pediatric oncology departments, hospitals offer advanced diagnostic tools, trained staff, and state-of-the-art facilities, enabling comprehensive care. Moreover, many clinical research studies on biomarkers are conducted in hospital settings, further driving their adoption. This infrastructure allows hospitals to cater to a large pediatric population, ensuring accurate diagnostics and personalized treatment plans, making them a cornerstone of the market.

Company Market Share

Key market players in the global market are strategically investing in product innovation and expanding their product portfolios to meet growing consumer demand for convenience, safety, and sustainability. Companies are focusing on developing personalized and targeted biomarkers that are effective in the early detection of cancer in the pediatric population, along with advanced tracking of progression.  

Caris Life Sciences: An emerging player in the Global Pediatric Cancer Biomarkers market

Caris Life Sciences is an emerging player in the global market. The company is gaining attention for its innovative approach to designing and developing advanced techniques to enhance human life and transform healthcare by utilizing innovative technologies such as whole transcriptome and exome sequencing with artificial intelligence and machine learning.

Recent developments at Caris Life Sciences include:

In March 2024, Caris Life Sciences entered into a partnership with Beat Childhood Cancer Research Consortiums, which is a network of 50 universities and children’s hospitals headquartered at Penn State College of Medicine in Pennslyvania, as they have a global network for clinical trials of pediatric cancer.

Recent Developments

1. October 2024 -Research published in Molecular Cancer revealed the discovery of molecular markers in blood linked to the future development of acute lymphoblastic leukemia (ALL), the most common pediatric cancer. This breakthrough enhances early detection, enabling timely intervention and improved treatment outcomes for children at risk.
2. September 2024 -Lunit partnered with Roche to integrate its Lunit SCOPE PD-L1 22C3 TPS into Roche’s Navify digital pathology platform. This collaboration aims to advance cancer diagnostics by combining cutting-edge AI-driven solutions with Roche’s established digital pathology tools, improving precision in pediatric oncology treatments.
3. August 2024 -Illumina Inc. announced FDA approval for its first two companion diagnostics (CDx) and in vitro diagnostics (IVD) TruSight Oncology (TSO) comprehensive test. This milestone enhances pediatric cancer biomarker diagnostics, offering a detailed genetic profiling tool for precision medicine in oncology.

Analyst Opinion

As per our analyst, the global market for pediatric cancer biomarkers is set for significant growth, fueled by the rising prevalence of pediatric cancer cases and the increasing adoption of liquid biopsy techniques. Government investments and focused research on rare cancers are creating a robust foundation for market expansion.

Moreover, collaborations between leading healthcare research firms and hospitals are enhancing the efficiency and effectiveness of innovative treatments, paving the way for improved outcomes in pediatric oncology care. These developments are anticipated to drive sustained growth and innovation.